A protein found in brown fat, but not typical white fat, is key to how the energy-burning brown fat cells function
While most fat cells in the human body store energy, everyone has a small subset of brown fat cells that do the opposite—burn energy and generate heat. Now, Salk researchers have discovered how the molecule ERR? gives this “healthier” brown fat its energy-expending identity, making those cells ready to warm you up when you step into the cold, and potentially offering a new therapeutic target for diseases related to obesity. The paper appears in Cell Reports on March 13, 2018.
“This not only advances our understanding of how the body responds to cold, but could lead to new ways to control the amount of brown fat in the body, which has links to obesity, diabetes and fatty liver disease,” says senior author Ronald Evans, Howard Hughes Medical Institute investigator and holder of Salk’s March of Dimes Chair in Molecular and Developmental Biology.
Until about a decade ago, scientists thought that only babies—who can’t yet shiver to warm up—had brown fat in their bodies. Studies have since shown that adults also have brown fat, albeit at much lower levels, and people with lower body mass indexes (BMIs) tend to have more of it. At a cellular level, brown fat cells are crammed full of energy-generating mitochondria, which give the cells their brown color.
In the new work, Evans’ group focused on estrogen-related receptor gamma (ERR?), a gene that is active at high levels in brown fat cells.
“We were interested in what maintains brown fat, even when we’re not exposed to cold all the time,” says Maryam Ahmadian, a Salk research associate and first author of the new paper.
The team found that brown fat cells express the ERR? gene all the time (not just in response to cold) and that white fat cells do not express the gene at all. And by studying mice lacking the gene for ERR? (and therefore unable to make the ERRy molecule), the team observed that all brown fat cells resembled white cells in these mice. Additionally, the animals were unable to maintain their body temperature when exposed to cold temperatures. While 80 percent of normal mice are able to handle a temperature drop, all mice lacking ERR? did not tolerate the cold. However, there was no difference in the metabolism or weight of the mice. Together, the experiments reveal that ERR? is key to helping brown fat maintain its identity and its ability to respond to cold.
Since the ERR? gene codes for a protein that can travel into the cell nucleus and directly control the expression of other genes, the team also probed which genes were mediated by ERR? in brown fat cells. They pinpointed a number of genes already known to be important in brown fat, but which hadn’t been specifically linked to ERR? inthe past.
“We uncovered the factors that are both involved in protection against the cold and underpin brown fat identity,” says Michael Downes, a Salk senior scientist and co–senior author of the paper.
The group is planning future studies that look at the effect of activating ERR? in white fat cells—which they suspect could make some white fat resemble brown fat, and potentially help treat obesity and diabetes. They also want to study whether the role of ERR? in the brown fat of humans is the same as what they’ve observed in mice.
Learn more: Molecule that gives energy-burning brown fat its identity could lead to drugs for obesity
The Latest on: Drug for obesity
[google_news title=”” keyword=”drug for obesity” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug for obesity
- 5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surgeon May 8, 2024 at 1:12 pm
Two pharmaceutical companies, Eli Lilly (LLY) and Novo Nordisk (NVO), are leading the weight-loss revolution with a new class of drugs known as GLP-1 agonists. Surging revenue and growing excitement ...
- New oral diabetes + obesity drug's India sales surge 100%on May 8, 2024 at 11:54 am
India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenges and evolving disease patterns as it grows as a superpower.
- Study Shows Endoscopic Sleeve Gastroplasty Outperforms Trendy Weight-Loss Drugson May 8, 2024 at 11:00 am
A study suggests endoscopic sleeve gastroplasty is a more cost-effective obesity treatment than new diet drugs.
- How Common Is Stomach Paralysis From Obesity Medication?on May 8, 2024 at 9:54 am
A few case reports of gastroparesis, or stomach paralysis, have surfaced in tandem with GLP-1 drugs. Here's what you need to know about the condition and how common it is, according to ...
- Decades-old law limits access to Wegovy for Medicaid beneficiarieson May 8, 2024 at 9:38 am
She is interested in new blockbuster drugs that help people with overweight and obesity. But she and her husband found themselves on Medicaid for the first time last year. Colorado's Medicaid plan won ...
- ‘Ozempic babies’: Reports of surprise pregnancies raise new questions about weight loss drugson May 8, 2024 at 7:00 am
Numerous women have shared stories of “Ozempic babies” on social media. But the joy some experience in discovering pregnancies may come with anxiety about the unknowns, as these medicines haven’t been ...
- States consider whether to add coverage for some obesity medicineson May 7, 2024 at 6:20 pm
Medicaid is required to cover almost all drugs, but Congress specifically excluded those for weight loss. Even so, 16 states now cover Wegovy. Others are considering it, but it could strain budgets.
- Amgen’s obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to comeon May 3, 2024 at 7:09 am
Fueled by upbeat management comments on an experimental obesity treatment, Amgen’s stock jumped more than 12% early Friday — and analysts see more gains ahead as the company maps out late-stage trials ...
- Novo Nordisk trims price for blockbuster obesity drug as competition heats upon May 2, 2024 at 5:02 pm
Novo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while competition from rival Eli Lilly forced the company to cut ...
via Bing News